If we properly select patients and match them to appropriate therapies based on their individual genomic signature, a high proportion may benefit. Recent efforts to systematically characterize the molecular basis of neuroblastoma confirm the biologic heterogeneity of the disease and reveal major molecular sub-types with varying prognoses, suggesting that different sub-types of neuroblastoma may respond to different therapeutic strategies. Purpose: The Neuroblastoma and Medulloblastoma Translational Research Consortium (NMTRC) opened the first FDA-approved study using molecular guided therapy in pediatric oncology focused in relapsed neuroblastoma. Louis, MO 4Pediatric Oncology, Levine Children's Hospital, Charlotte, NC 5Pediatric Oncology, Medical University of South Carolina, Charleston, SC 6Pediatric Oncology, Helen DeVos Children's Hospital, Grand Rapids, MI 7Pediatric Oncology, Connecticut Children's Medical Center, Hartford, CT 8Pediatric Oncology, Rady's Children's Hospital, San Diego, CA 9Pediatric Oncology, Van Andel Research Institute, Grand Rapids, MI, USA Giselle Sholler 1, Don Eslin 2, William Ferguson 3, Joel Kaplan 4, Jacqueline Kraveka 5, Deanna Mitchell 6, Nehal Parikh 7, William Roberts 8, Craig Webb 9ġPediatric Oncology, Van Andel Research Institute/Helen DeVos Children's Hospital, Grand Rapids, MI 2Pediatric Oncology, MD Anderson Orlando, Orlando, FL 3Pediatric Oncolgoy, Cardinal Glennon Children's Hospital, St. PERSONALIZED TREATMENT APPROACHES IN NEUROBLASTOMA Efforts were made to establish structures ensuring homogeneous approaches for proton beam treatments, documentation and evaluation within the GPOH network. Two more centers are expected to start operation in the future.Ĭonclusion: Proton beam therapy will be an important corner stone of multimodality care in the pediatric cohort in Germany. A central documentation of performed treatments and side effects in the RiSK registry is ongoing. Two German facilities have started clinical operation providing proton beam treatment for children even when sedation is required. A central reference and review board for particle therapy was established (funded by the Deutsche Kinderkrebsstiftung) providing support for referring centers, treating facilities and affected families also. HIT LGG, HIT 2000, CWS guidance, EURO-Ewing, EURAMOS/COSS, ATRT/EURHAB, Craniopharyngeom), each of them having one particle therapist in their study boards. Results: Proton therapy was managed to become part of the majority of the pediatric protocols (i.e. The German working group of Pediatric Radiation Oncology (APRO) has established a task group for innovative radiotherapy and particle therapy in order to form a homogenous approach and to enable exchange of knowledge and common guidelines for all up-coming centers.
![qarc medulloblastoma atlas qarc medulloblastoma atlas](https://oaepublishstorage.blob.core.windows.net/4625f9fd-cba0-4b4b-8342-f407c61bf310/2864.fig.4.jpg)
Treatments for German kids were performed according to the interdisciplinary protocols of the German Society for Pediatric Oncology and Hematology (GPOH) as an alternative to conventional techniques. All data were registered into the German RiSK registry and QoL evaluation performed in cooperation with the German PedQoL tools. Methods: Since 2004, German patients were referred to the Paul Scherrer Institute (PSI), Switzerland, for treatment of CNS tumours and sarcomas.
![qarc medulloblastoma atlas qarc medulloblastoma atlas](https://i.ytimg.com/vi/XZ3Qy4K_9Es/hqdefault.jpg)
Therefore, in Germany, proton beam therapy is going to be part of the future multimodality cancer concepts. Purpose: Proton beam therapy seems to offer significant advantages over conventional techniques especially for the pediatric cohort. West German Proton Therapy Center, University Hospital Essen, Essen, Germany 44 th CONGRESS OF THE INTERNATIONAL SOCIETY OF PAEDIATRIC ONCOLOGY (SIOP) 2012 LONDON, UNITED KINGDOM, 5 th–8 th OCTOBER, 2012 SIOP ABSTRACTS SYMPOSIA ABSTRACTS SYMPOSIUM 1 PROTON BEAM THERAPY IN CHILDREN THE GERMAN CONCEPT